Flu

Biography

Pamuk Bilsel, Ph.D. is Chief Scientific Officer at FluGen, Inc. Prior to joining FluGen in 2008 as head of Research and Development, she was at Pharmexa-Epimmune where she served as Director of Molecular Biology and developed DNA vaccines based on cell mediated immunity against influenza and malaria. At Pentamer Pharmaceuticals, a San Diego start-up venture, she worked on subunit vaccines against respiratory syncitial virus using virus-like particle technology. Preceding that Dr. Bilsel worked at Aviron generating live attenuated influenza vaccine strains in addition to studies with the cold-adapted influenza vaccine which was eventually launched as MedImmune’s FluMist®. Dr Bilsel received her Ph.D. in Cell and Molecular Biology from the University of Nevada, Reno and did her post-doctoral training at St. Jude Children’s Research Hospital with Dr. Yoshihiro Kawaoka.

Research Interest

Dr. Bilsel brings nearly 15 years of corporate biotechnology and management experience in vaccine research against infectious diseases. Prior to joining FluGen, she was involved in developing DNA vaccines based on cell mediated immunity against influenza and malaria at Pharmexa-Epimmune where she served as Director of Molecular Biology.